Home Tags TRPH-222

Tag: TRPH-222

Catalent’s SMARTag® ADC Stands Out in the Crowd of HER2-targeted Conjugates

The steadily growing number of HER2-targeted antibody-drug conjugates (ADCs) in preclinical development is a testament to the success of the original anti-HER2 ADC, ado-trastuzumab...

Interim Results of Phase I Clinical Trial of TRPH-222 in R/R...

The investigational drug TRPH-222 (previously known as CAT-02-106), a next-generation antibody-drug conjugate (ADC), is demonstrating early signs of efficacy in the interim results of...

Triphase’s TRPH-222 enters Clinical Phase I trials

Triphase Accelerator’s TRPH-222, an anti-CD22 antibody-drug conjugate (ADC) for the treatment of patients with lymphoma, has been dosed in the first patient in a...

TRPH-222, a Novel Anti-CD22 ADC, has Significant Anti-Tumor Activity in NHL

A preclinical abstract describing TRPH-222, also known as CAT-02-106, an anti-CD22 antibody-drug conjugate or ADC being developed by Triphase Accelerator for the treatment of...